Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
5.78
+0.04 (0.70%)
Nov 2, 2026, 12:23 PM EST - Market open
Phathom Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 184.56 | 129.97 | 297.26 | 381.39 | 155.39 | 183.26 |
Cash & Short-Term Investments | 184.56 | 129.97 | 297.26 | 381.39 | 155.39 | 183.26 |
Cash Growth | 36.55% | -56.28% | -22.06% | 145.45% | -15.21% | -36.26% |
Receivables | 107.6 | 78.13 | 38.8 | 1.64 | - | - |
Inventory | 7.63 | 5.52 | 3.21 | 1.21 | - | - |
Prepaid Expenses | 8.22 | 15.35 | 20.87 | 13.19 | 5.13 | 3.27 |
Total Current Assets | 308.01 | 228.97 | 360.13 | 397.43 | 160.51 | 186.53 |
Property, Plant & Equipment | 3.25 | 3.67 | 2.09 | 3.62 | 3.49 | 2.56 |
Other Long-Term Assets | 33.76 | 26.51 | 16.1 | 12.79 | 0.8 | 0.34 |
Total Assets | 345.02 | 259.15 | 378.32 | 413.84 | 164.81 | 189.43 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 11.11 | 4.98 | 10.51 | 12.6 | 10 | 5.15 |
Accrued Expenses | 122.6 | 91.66 | 54.94 | 18.34 | 15.53 | 13.28 |
Current Portion of Long-Term Debt | 40.52 | 27.25 | 19.78 | 7.11 | - | - |
Current Portion of Leases | 0.67 | 0.65 | 0.5 | 0.73 | 0.71 | 0.49 |
Other Current Liabilities | - | 7.5 | - | - | - | - |
Total Current Liabilities | 174.9 | 132.04 | 85.73 | 38.78 | 26.24 | 18.92 |
Long-Term Debt | 512.51 | 559.21 | 534.67 | 437.66 | 204.79 | 89.67 |
Long-Term Leases | 1.74 | 2.07 | - | 0.46 | 1.1 | 1.18 |
Other Long-Term Liabilities | 3.5 | 4 | 11.5 | 9.7 | 7.5 | 7.5 |
Total Liabilities | 692.66 | 697.32 | 631.9 | 486.6 | 239.62 | 117.28 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-In Capital | 1,198 | 1,046 | 1,009 | 855.92 | 652.28 | 601.52 |
Retained Earnings | -1,546 | -1,484 | -1,263 | -928.69 | -727.09 | -529.37 |
Shareholders' Equity | -347.64 | -438.17 | -253.58 | -72.76 | -74.81 | 72.16 |
Total Liabilities & Equity | 345.02 | 259.15 | 378.32 | 413.84 | 164.81 | 189.43 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 555.45 | 589.17 | 554.95 | 445.96 | 206.6 | 91.34 |
Net Cash (Debt) | -370.89 | -459.2 | -257.69 | -64.56 | -51.21 | 91.92 |
Net Cash Growth | - | - | - | - | - | -61.46% |
Net Cash Per Share | -4.57 | -6.30 | -4.08 | -1.26 | -1.31 | 2.48 |
Filing Date Shares Outstanding | 81.29 | 78.8 | 69.64 | 58.48 | 41.72 | 30.57 |
Total Common Shares Outstanding | 81.22 | 71.42 | 68.52 | 57.97 | 41.47 | 30.51 |
Working Capital | 133.11 | 96.93 | 274.41 | 358.65 | 134.28 | 167.61 |
Book Value Per Share | -4.28 | -6.14 | -3.70 | -1.26 | -1.80 | 2.36 |
Tangible Book Value | -347.64 | -438.17 | -253.58 | -72.76 | -74.81 | 72.16 |
Tangible Book Value Per Share | -4.28 | -6.14 | -3.70 | -1.26 | -1.80 | 2.36 |
Machinery | - | 4.3 | 4.16 | 4.05 | 2.16 | 1.43 |
Construction In Progress | - | - | - | - | 0.4 | - |
Leasehold Improvements | - | 0.24 | 0.16 | 0.14 | 0.12 | 0.08 |